Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.

"Competing interests: SL, NPS, JS and EM report grants from The Research Council of Norway and from The South-Eastern Norway Regional Health Authority during the conduct of the study. ABA reports personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from Pfizer, outside the submitted work. ICO, HF, CS, ÅL, IMH have nothing to disclose. CAH reports personal fees from Novartis, outside the submitted work. GB reports personal fees from Novartis, personal fees from UCB, outside the submitted work. HH reports personal fees from Novartis, outside the submitted work. TU reports personal fees from Galapagos, personal fees from Lilly, personal fees from Novartis, personal fees from Pfizer, personal fees from UCB, outside the submitted work. DHS reports that Abbvie donated drugs for a trial, that Amgen donated drugs for a trial, grants from Corrona, grants from Janssen, grants from Pfizer, grants from Roche/Genentech, outside the submitted work. DvdH reports personal fees from AbbVie, personal fees from Amgen, personal fees from Astellas, personal fees from AstraZeneca, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from Celgene, personal fees from Cyxone, personal fees from Daichii, personal fees from Eisai, personal fees from Eli Lilly, personal fees from Galapagos, personal fees from Gilead, personal fees from GSK, personal fees from Janssen, personal fees from Merck, personal fees from Novartis, personal fees from Pfizer, personal fees from Regeneron, personal fees from Roche, personal fees from Sanofi, personal fees from Takeda, personal fees from UCB Pharma, outside the submitted work; and is Director Imaging Rheumatology BV. TKK reports grants and personal fees from AbbVie, personal fees from Biogen, personal fees from Celltrion, personal fees from Egis, personal fees from Lilly, grants and personal fees from MSD, personal fees from Mylan, personal fees from Hikma, grants and personal fees from Novartis, personal fees from Oktal, personal fees from Orion Pharma, grants and personal fees from Pfizer, personal fees from Roche, personal fees from Sandoz, personal fees from Sanofi, grants and personal fees from UCB, grants from BMS, outside the submitted work. EAH reports grants from The Research Council of Norway, grants from The South-Eastern Norway Regional Health Authority, during the conduct of the study; personal fees from Pfizer, personal fees from AbbVie, personal fees from Janssen-Cilag, personal fees from Gilead, personal fees from UCB Pharma, personal fees from Celgene, personal fees from Lilly, personal fees from Roche, outside the submitted work."

"Funding: Research Council of Norway and South-Eastern Norway Regional Health Authority."

"Trial registration numbers EudraCT: 2012-005275-14 and clinicaltrials.gov: NCT01881308."